Affinity Capital Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Affinity Capital Advisors’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-433	Closed	-$3.51K	–	139
2023 Q1	$3.51K	Buy	433 +65	+18%	+$863	﹤0.01%	123
2022 Q4	$4.37K	Buy	368 +68	+23%	+$777	﹤0.01%	108
2022 Q3	$4K	Buy	300 +112	+60%	+$2.89K	﹤0.01%	106
2022 Q2	$7K	Hold	188	–	–	﹤0.01%	108
2022 Q1	$8K	Hold	188	–	–	﹤0.01%	113
2021 Q4	$8K	Hold	188	–	–	﹤0.01%	123
2021 Q3	$13K	Buy	+188	New	+$13.8K	﹤0.01%	120

Other funds holding DMK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Affinity Capital Advisors's DMK Position: Q2 2023 in Review

Affinity Capital Advisors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2023, closing a stake of 433 shares — an estimated $3.51K sold.

Affinity Capital Advisors first reported a position in DMK in Q3 2021 and held it in 7 quarters. The position peaked at $13K in Q3 2021. 22 funds tracked by Wall St. Rank hold DMK as of Q2 2023.

Affinity Capital Advisors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2023 after selling out during the quarter.
Affinity Capital Advisors sold 433 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2023, an estimated $3.51K.
Affinity Capital Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2021 and held it in 7 quarters.
Affinity Capital Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $13K in Q3 2021.
22 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2023.

Based on Affinity Capital Advisors's 13F filing for Q2 2023, filed 14 Jul 2023.